{"id":7691,"date":"2024-06-20T11:38:07","date_gmt":"2024-06-20T16:38:07","guid":{"rendered":"https:\/\/labtesting.\/?p=7691"},"modified":"2024-06-20T11:39:36","modified_gmt":"2024-06-20T16:39:36","slug":"ind-studies-understanding-early-stage-regulatory-needs","status":"publish","type":"post","link":"https:\/\/labtesting.\/2024\/06\/20\/ind-studies-understanding-early-stage-regulatory-needs\/","title":{"rendered":"IND Studies: Understanding Early-Stage Regulatory Needs"},"content":{"rendered":"\n

Bringing new drugs and therapeutics to a global market requires extensive planning. Requirements for soliciting early-stage regulatory feedback differ across geographies, so it might be tempting to file new drug submissions separately. However, planning a comprehensive global IND submission can save developers time and money.<\/p>\n\n\n\n

The importance of a global program <\/h3>\n\n\n\n

A global IND program can eliminate the need for duplicate studies, enabling a faster expansion into foreign markets. To secure the best possible outcome, developers should file a global IND submission at the beginning of the planning phase, and with foresight, they can ensure all studies adhere to regulations across the world.  <\/p>\n\n\n\n

The major differences between regulatory requirements can be categorized into three areas:<\/p>\n\n\n\n